International Journal of Antimicrobial Agents

Article	Citations
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges	3621
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial	3237
Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality	1254
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?	714
Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence	700
Coronavirus disease 2019 (COVID-19): current status and future perspectives	687
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19	617
The epidemiology, diagnosis and treatment of COVID-19	598
Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection	418
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies	381
Chloroquine for the 2019 novel coronavirus SARS-CoV-2	302
Global epidemiology of coronavirus disease 2019 (COVID-19): disease incidence, daily cumulative index, mortality, and their association with country healthcare resources and economic status	255
Arguments in favour of remdesivir for treating SARS-CoV-2 infections	239
Increased antimicrobial resistance during the COVID-19 pandemic	237
Extra-respiratory manifestations of COVID-19	218
Computational screening of antagonists against the SARS-CoV-2 (COVID-19) coronavirus by molecular docking	195
Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies	183
SARS-CoV-2 was already spreading in France in late December 2019	183
Teicoplanin: an alternative drug for the treatment of COVID-19?	182
Procalcitonin levels in COVID-19 patients	179
Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking trimerization of the spike glycoprotein	175
Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine	158
Pseudomonas aeruginosa epidemic high-risk clones and their association with horizontally-acquired β-lactamases: 2020 update	145
Tocilizumab for severe COVID-19: a systematic review and meta-analysis	129
COVID-19 treatment: close to a cure? A rapid review of pharmacotherapies for the novel coronavirus (SARS-CoV-2)	126

Recent progress in understanding 2019 novel coronavirus (SARS-CoV-2) associated with human respiratory disease: detection, mechanisms and treatment	114
Different mutations in SARS-CoV-2 associate with severe and mild outcome	113
Ribavirin therapy for severe COVID-19: a retrospective cohort study	112
Lactoferrin as potential preventative and adjunct treatment for COVID-19	109
Low-dose hydroxychloroquine therapy and mortality in hospitalised patients with COVID-19: a nationwide observational study of 8075 participants	96
Pharmacological perspective: glycyrrhizin may be an efficacious therapeutic agent for COVID-19	95
Drug repositioning is an alternative for the treatment of coronavirus COVID-19	86
Diagnostic performance of initial blood urea nitrogen combined with D-dimer levels for predicting in-hospital mortality in COVID-19 patients	85
Successful treatment with plasma exchange followed by intravenous immunoglobulin in a critically ill patient with COVID-19	82
Neutrophil-to-lymphocyte ratio and clinical outcome in COVID-19: a report from the Italian front line	81
A review on possible modes of action of chloroquine/hydroxychloroquine: repurposing against SAR-CoV-2 (COVID-19) pandemic	79
Amantadine disrupts lysosomal gene expression: A hypothesis for COVID19 treatment	79
COVID-19 in the Eastern Mediterranean Region and Saudi Arabia: prevention and therapeutic strategies	79
COVID-19 outpatients: early risk-stratified treatment with zinc plus low-dose hydroxychloroquine and azithromycin: a retrospective case series study	79
Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal	78
Macrolides and viral infections: focus on azithromycin in COVID-19 pathology	78
Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19	77
Chloroquine and hydroxychloroquine in coronavirus disease 2019 (COVID-19). Facts, fiction and the hype: a critical appraisal	75
Review of: “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Gautret et al 2010, DOI:10.1016/j.ijantimicag.2020.105949	72
Safety and effectiveness of azithromycin in patients with COVID-19: An open-label randomised trial	67
Potential of coronavirus 3C-like protease inhibitors for the development of new anti-SARS-CoV-2 drugs: Insights from structures of protease and inhibitors	67
Searching for drugs for Chagas disease, leishmaniasis and schistosomiasis: a review	63
Long-acting drugs and formulations for the treatment and prevention of HIV infection	63
Emerging Co-Pathogens: New Delhi Metallo-beta-lactamase producing Enterobacterales Infections in New York City COVID-19 Patients	58
Combating devastating COVID-19 by drug repurposing	56
SARS-CoV-2: fear versus data	56
Therapeutic plasma exchange in patients with life-threatening COVID-19: a randomised controlled clinical trial	56
Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli	53
Widely available lysosome targeting agents should be considered as potential therapy for COVID-19	51
Addressing the challenges in antisepsis: focus on povidone iodine	51
Can post-exposure prophylaxis for COVID-19 be considered as an outbreak response strategy in long-term care hospitals?	51
Methylene blue inhibits replication of SARS-CoV-2 in vitro	50
Erratum to ``A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence'' [International Journal of Antimicrobial Agents 55/6 (2020) 105948]	50
Inhibition of the replication of SARS-CoV-2 in human cells by the FDA-approved drug chlorpromazine	48
Systematic review of the impact of appropriate versus inappropriate initial antibiotic therapy on outcomes of patients with severe bacterial infections	46
HIV-1 integrase strand transfer inhibitors: a review of current drugs, recent advances and drug resistance	46
Safety and efficacy of artemisinin-piperaquine for treatment of COVID-19: an open-label, non-randomised and controlled trial	45
Targeting antimicrobial drug resistance with marine natural products	44
Cardiac effects and toxicity of chloroquine: a short update	43
Contributions of insertion sequences conferring colistin resistance in Klebsiella pneumoniae	42
Colistin heteroresistance in Acinetobacter spp.: systematic review and meta-analysis of the prevalence and discussion of the mechanisms and potential therapeutic implications	41
A COVID-19 prophylaxis? Lower incidence associated with prophylactic administration of ivermectin	40
Side effects of ruxolitinib in patients with SARS-CoV-2 infection: Two case reports	39
Is teicoplanin a complementary treatment option for COVID-19? The question remains	38
In vitro activity of olorofim (F901318) against fungi of the genus, Scedosporium and Rasamsonia as well as against Lomentospora prolificans, Exophiala dermatitidis and azole-resistant Aspergillus fumi	37
Klebsiella pneumoniae infections in COVID-19 patients: a 2-month retrospective analysis in an Italian hospital	36
Octenidine: Novel insights into the detailed killing mechanism of Gram-negative bacteria at a cellular and molecular level	36
Colistin interacts synergistically with echinocandins against Candida auris	36
In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection	35
Excessive lysosomal ion-trapping of hydroxychloroquine and azithromycin	35

A pharmacological perspective of chloroquine in SARS-CoV-2 infection: An old drug for the fight against a new coronavirus?	35
Diagnosis and management of infections caused by multidrug-resistant bacteria: guideline endorsed by the Italian Society of Infection and Tropical Diseases (SIMIT), the Italian Society of Anti-Infecti	34
KPC-2-producing Klebsiella pneumoniae ST147 in a neonatal unit: Clonal isolates with differences in colistin susceptibility attributed to AcrAB-TolC pump	34
Emergence of a novel conjugative hybrid virulence multidrug-resistant plasmid in extensively drug-resistant Klebsiella pneumoniae ST15	34
Ceftolozane/tazobactam for difficult-to-treat Pseudomonas aeruginosa infections: A systematic review of its efficacy and safety for off-label indications	33
Clinical data from studies involving novel antibiotics to treat multidrug-resistant Gram-negative bacterial infections	33
Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals	33
Reduced nephrotoxicity with vancomycin therapeutic drug monitoring guided by area under the concentration–time curve against a trough 15–20 μg/mL concentration	33
High-dose ivermectin for early treatment of COVID-19 (COVER study): a randomised, double-blind, multicentre, phase II, dose-finding, proof-of-concept clinical trial	32
High prevalence of colistin resistance and mcr-9/10 genes in Enterobacter spp. in a tertiary hospital over a decade	32
Coronavirus disease 2019 (COVID-19): first indication of efficacy of Gene-Eden-VIR/Novirin in SARS-CoV-2 infection	32
Whole-genome sequencing in drug susceptibility testing of Mycobacterium tuberculosis in routine practice in Lyon, France	32
Interregional spread in Spain of linezolid-resistant Enterococcus spp. isolates carrying the optrA and poxtA genes	31
A pharmacist-led prospective antibiotic stewardship intervention improves compliance to community-acquired pneumonia guidelines in 39 public and private hospitals across South Africa	31
Identification of mobile colistin resistance genes (mcr-1.1, mcr-5 and mcr-8.1) in Enterobacteriaceae and Alcaligenes faecalis of human and animal origin, Nigeria	30
Oxygenated elansolid-type of polyketide spanned macrolides from a marine heterotrophic Bacillus as prospective antimicrobial agents against multidrug-resistant pathogens	29
Artemisinin elevates ergosterol levels of Candida albicans to synergise with amphotericin B against oral candidiasis	29
Bacteriophage–antibiotic combinations against ciprofloxacin/ceftriaxone-resistant Escherichia coli in vitro and in an experimental Galleria mellonella model	28
Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients	28
Epidemiology and prevalence of extended-spectrum β-lactamase- and carbapenemase-producing Enterobacteriaceae in humans, animals and the environment in West and Central Africa	28
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial revisited	28
In vitro efficacy of imipenem-relebactam and cefepime-AAI101 against a global collection of ESBL-positive and carbapenemase-producing Enterobacteriaceae	28
An update on the clinical pharmacology of miltefosine in the treatment of leishmaniasis	28
Chloroquine as a prophylactic agent against COVID-19?	27
Miltefosine as an alternative strategy in the treatment of the emerging fungus Candida auris	27
Clinical and Microbiological Analysis of Risk Factors for Mortality in Patients with Carbapenem-Resistant Enterobacteriaceae Bacteremia	26
Comparison of dalbavancin to standard-of-care for outpatient treatment of invasive Gram-positive infections	26
Treatment of osteoarticular, cardiovascular, intravascular-catheter-related and other complicated infections with dalbavancin and oritavancin: A systematic review	26
COVID-19 in hospitalised patients in Spain: a cohort study in Madrid	26
Diversity of amino acid substitutions in PmrCAB associated with colistin resistance in clinical isolates of Acinetobacter baumannii	26
Reply to Gautret et al: hydroxychloroquine sulfate and azithromycin for COVID-19: what is the evidence and what are the risks?	26
Inactivation of mgrB gene regulator and resistance to colistin is becoming endemic in carbapenem-resistant Klebsiella pneumoniae in Greece: A nationwide study from 2014 to 2017	26
Ceftazidime-avibactam in the treatment of infections caused by KPC-producing Klebsiella pneumoniae: factors associated with clinical efficacy in a single-center cohort	25
Antimicrobial stewardship programme: a vital resource for hospitals during the global outbreak of coronavirus disease 2019 (COVID-19)	25
Effect of antibiotics on the human microbiome: a systematic review	25
Dysbiosis of the rat vagina is efficiently rescued by vaginal microbiota transplantation or probiotic combination	25
Extended-spectrum β-lactamase-producing Escherichia coli from extraintestinal infections in humans and from food-producing animals in Italy: a ‘One Health’ study	24
Tocilizumab in COVID-19: Beware the risk of intestinal perforation	24
Is colistin-associated acute kidney injury clinically important in adults? A systematic review and meta-analysis	24
Pan-resistant Candida auris isolates from the outbreak in New York are susceptible to ibrexafungerp (a glucan synthase inhibitor)	24
Antimicrobial stewardship in the ICU in COVID-19 times: the known unknowns	24
Genomic analysis of a pan-resistant Klebsiella pneumoniae sequence type 11 identified in Japan in 2016	23
Corticosteroid therapy for patients with COVID-19 pneumonia: a before–after study	23
An insight into the implementation of the global action plan on antimicrobial resistance in the WHO African region: A roadmap for action	23
Co-occurrence of aminoglycoside and β-lactam resistance mechanisms in aminoglycoside- non-susceptible Escherichia coli isolated in the Zurich area, Switzerland	23
Multidrug-resistant high-risk Enterococcus faecium clones: can we really define them?	23
Dissemination of carbapenem-resistant Pseudomonas aeruginosa isolates and their susceptibilities to ceftolozane-tazobactam in Germany	23
Repositioning of non-antibiotic drugs as an alternative to microbial resistance: a systematic review	23
Antivirulence activity of auranofin against vancomycin-resistant enterococci: in vitro and in vivo studies	23
Carbapenemase-producing Pseudomonas aeruginosa in Spain: interregional dissemination of the high-risk clones ST175 and ST244 carrying blaVIM-2, blaVIM-1, blaIMP-8, blaVIM-20 and blaKPC-2	22
Evaluation of peptoid mimics of short, lipophilic peptide antimicrobials	22
Use of continuous-infusion ceftolozane/tazobactam for resistant Gram-negative bacterial infections: a retrospective analysis and brief review of the literature	22
Clinical outcomes of Stenotrophomonas maltophilia infection treated with trimethoprim/sulfamethoxazole, minocycline, or fluoroquinolone monotherapy	22
Activity of ceftolozane-tazobactam against Gram-negative pathogens isolated from lower respiratory tract infections in the Asia-Pacific region: SMART 2015-2016	22
Combination ceftaroline and daptomycin salvage therapy for complicated methicillin-resistant Staphylococcus aureus bacteraemia compared with standard of care	22
Pharmacokinetics and safety of posaconazole intravenous solution and powder for oral suspension in children with neutropenia: an open-label, sequential dose-escalation trial	22
Design of novel viral attachment inhibitors of the spike glycoprotein (S) of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) through virtual screening and dynamics	21
Synergism of sophoraflavanone G with norfloxacin against effluxing antibiotic-resistant Staphylococcus aureus	21
Pharmacokinetics and Pharmacodynamics of Ceftolozane/Tazobactam in Critically Ill Patients With Augmented Renal Clearance	21
Pattern of SARS-CoV-2 infection among dependant elderly residents living in long-term care facilities in Marseille, France, March–June 2020	21
Distribution of mcr genes among carbapenem-resistant Enterobacterales clinical isolates: high prevalence of mcr-positive Enterobacter cloacae complex in Seoul, Republic of Korea	21
Comparison of linezolid step-down therapy to standard parenteral therapy in methicillin-resistant Staphylococcus aureus bloodstream infections	21
Prevalence of ESBL non-CRE Escherichia coli and Klebsiella pneumoniae among clinical isolates collected by the SMART global surveillance programme from 2015 to 2019	21
Co-existence of the oxazolidinone resistance genes cfr and optrA on two transferable multi-resistance plasmids in one Enterococcus faecalis isolate from swine	20
Ceftazidime-avibactam activity against a challenge set of carbapenem-resistant Enterobacterales: Ompk36 L3 alterations and β-lactamases with ceftazidime hydrolytic activity lead to elevated MIC values	20
A four-probiotic preparation for ventilator-associated pneumonia in multi-trauma patients: results of a randomized clinical trial	20
Molecular basis of antimicrobial resistance in Mycoplasma genitalium	20
β-lactam antibiotic versus combined β-lactam antibiotics and single daily dosing regimens of aminoglycosides for treating serious infections: A meta-analysis	20
Entecavir therapy reverses gut microbiota dysbiosis induced by hepatitis B virus infection in a mouse model	20
Circulation of multi-drug-resistant Shigella sonnei and Shigella flexneri among men who have sex with men in Barcelona, Spain, 2015–2019	20
Phenotypic and molecular characterizations of carbapenem-resistant Acinetobacter baumannii isolates collected within the EURECA study	20
Colistin: from the shadows to a One Health approach for addressing antimicrobial resistance	19
The current state of laboratory mycology in Asia/Pacific: A survey from the European Confederation of Medical Mycology (ECMM) and International Society for Human and Animal Mycology (ISHAM)	19
COVID-19 Therapeutic and Prevention	19
RamA upregulates multidrug resistance efflux pumps AcrAB and OqxAB in Klebsiella pneumoniae	19
Effectiveness of ceftazidime-avibactam for the treatment of infections due to Pseudomonas aeruginosa	19
Polymyxin resistance in Enterobacterales: overview and epidemiology in the Americas	19
Biofilm-active antibiotic treatment improves the outcome of knee periprosthetic joint infection: Results from a 6-year prospective cohort study	19
Carbapenemase-producing Enterobacterales infections: recent advances in diagnosis and treatment	19
Usefulness of therapeutic drug monitoring in estimating the duration of dalbavancin optimal target attainment in staphylococcal osteoarticular infections: a proof-of-concept	19

Antibacterial activity of griseofulvin analogues as an example of drug repurposing	19
Randomised controlled trials for COVID-19: evaluation of optimal randomisation methodologies—need for data validation of the completed trials and to improve ongoing and future randomised trial designs	19
Therapeutic modalities and novel approaches in regenerative medicine for COVID-19	18
Multicenter study of ceftolozane/tazobactam for treatment of Pseudomonas aeruginosa infections in critically ill patients	18
In vitro activity of cefiderocol against aerobic Gram-negative bacterial pathogens from Germany	18
Azithromycin and ambroxol as potential pharmacotherapy for SARS-CoV-2	18
Cross-border emergence of clonal lineages of ST38 Escherichia coli producing the OXA-48-like carbapenemase OXA-244 in Germany and Switzerland	18
Comparison of single-dose fosfomycin tromethamine and other antibiotics for lower uncomplicated urinary tract infection in women and asymptomatic bacteriuria in pregnant women: A systematic review and	18
In vitro activity of ceftazidime-avibactam against Gram-negative isolates collected in 18 European countries, 2015–2017	18
Effect of hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, an update with an intention-to-treat analysis and clinical outcomes	18
In vitro activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa causing urinary, intra-abdominal and lower respiratory tract infections in intensive care units in Portu	17
Evaluation of area under the concentration–time curve-guided vancomycin dosing with or without piperacillin-tazobactam on the incidence of acute kidney injury	17
Hot topics in diabetic foot infection	17
Candida albicans biofilms: antifungal resistance, immune evasion, and emerging therapeutic strategies	17
Fosfomycin for bacterial prostatitis: a review	17
Colistin resistance genes mcr-1 to mcr-5, including a case of triple occurrence (mcr-1, -3 and -5), in Escherichia coli isolates from faeces of healthy pigs, cattle and poultry in Belgium, 2012–2016	17
Plasma exchange in the treatment of complex COVID-19-related critical illness: controversies and perspectives	17
Management of infections caused by WHO critical priority Gram-negative pathogens in Arab countries of the Middle East: a consensus paper	17
Antibiotic pharmacokinetic/pharmacodynamic modelling: MIC, pharmacodynamic indices and beyond	17
Therapeutic drug monitoring of commonly used anti-infective agents: A nationwide cross-sectional survey of Australian hospital practices	17
What is the optimal loading dose of broad-spectrum β-lactam antibiotics in septic patients? Results from pharmacokinetic simulation modelling	17
The Novel Membrane-Associated Auxiliary Factors AuxA and AuxB Modulate β-lactam Resistance in MRSA by stabilizing Lipoteichoic Acids	17
Heteroresistance to cefepime in Pseudomonas aeruginosa bacteraemia	16
SUsceptibility and Resistance to Fosfomycin and other antimicrobial agents among pathogens causing lower urinary tract infections: findings of the SURF study	16
In vitro synergistic activity of NCL195 in combination with colistin against Gram-negative bacterial pathogens	16
Klebsiella pneumoniae Harboring Carbapenemase Genes in Taiwan: Its Evolution over 20 Years, 1998–2019	16
Pharmacodynamics of immune response biomarkers of interest for evaluation of treatment effects in bacterial infections	16
Genomic and phenotypic characterisation of antimicrobial resistance in carbapenem-resistant Acinetobacter baumannii hyperendemic clones CC1, CC15, CC79 and CC25	16
Office-based approach to urinary tract infections in 50 000 patients: results from the REWIND study	16
Effect of initial antifungal therapy on mortality among patients with bloodstream infections with different Candida species and resistance to antifungal agents: A multicentre observational study by th	16
Complex emergencies of COVID-19: management and experience in Zhuhai, China	16
Spinal implant-associated infections: a prospective multicentre cohort study	16
Piperacillin-Tazobactam-Resistant/Third-Generation Cephalosporin-Susceptible Escherichia coli and Klebsiella pneumoniae Isolates: Resistance Mechanisms and In vitro-In vivo Discordance	16
Change in Antimicrobial Use During COVID-19 Pandemic in South Carolina Hospitals: A Multicenter Observational Cohort Study	16
Evolutionary landscapes of Pseudomonas aeruginosa towards ribosome-targeting antibiotic resistance depend on selection strength	16
A descriptive pharmacokinetic/pharmacodynamic analysis of continuous infusion ceftazidime-avibactam in a case series of critically ill renal patients treated for documented carbapenem-resistant Gram-n	16
Adaptation of a Russian population to SARS-CoV-2: Asymptomatic course, comorbidities, mortality, and other respiratory viruses – A reply to Fear versus Data	15
Dalbavancin and telavancin in the treatment of infective endocarditis: a literature review	15
Pharmacokinetics and pharmacodynamics of antibiotics in cystic fibrosis: a narrative review	15
Effects of Hydroxychloroquine on Covid-19 in Intensive Care Unit Patients: Preliminary Results	15
Current trends in the real-life use of dalbavancin: report of a study panel	15
Antimicrobial production by strictly anaerobic Clostridium spp.	15
Plasma medicine and wound management: Evaluation of the antibacterial efficacy of a medically certified cold atmospheric argon plasma jet	15
Publishing in face of the COVID-19 pandemic	15
Pharmacokinetic/pharmacodynamic adequacy of polymyxin B against extensively drug-resistant Gram-negative bacteria in critically ill, general ward and cystic fibrosis patient populations	15
Assessment of the in vitro activity of ceftazidime/avibactam against a global collection of multidrug-resistant Klebsiella spp. from the INFORM surveillance programme (2015–2017)	15
Drug-Drug Interactions Potential of Direct-Acting Antivirals for the treatment of Chronic Hepatitis C Virus infection	15
Phenotypic and WGS-derived antimicrobial resistance profiles of clinical and non-clinical Acinetobacter baumannii isolates from Germany and Vietnam	14
Acute kidney injury with combination vancomycin and piperacillin-tazobactam therapy in the ICU: A retrospective cohort study	14
How preclinical infection models help define antibiotic doses in the clinic	14
LPD-12: a promising lipopeptide to control COVID-19	14
Recommended Antibiotic Dosage Regimens in Critically Ill Patients with Augmented Renal Clearance: A Systematic Review	14
Effects of simeprevir on the replication of SARS-CoV-2 in vitro and in transgenic hACE2 mice	14
Widespread high-risk clones of multidrug-resistant extended-spectrum β-lactamase-producing Escherichia coli B2-ST131 and F-ST648 in public aquatic environments	14
Efficacy of newly generated short antimicrobial cationic lipopeptides against methicillin-resistant Staphylococcus aureus (MRSA)	13
Vertical transmission and kidney damage in newborns whose mothers had coronavirus disease 2019 during pregnancy	13
In vitro characterization, ADME analysis, and histological and toxicological evaluation of BM1, a macrocyclic amidinourea active against azole-resistant Candida strains	13
Post-exposure prophylaxis with hydroxychloroquine for the prevention of COVID-19, a myth or a reality? The PEP-CQ Study	13
Quasispecies dynamics and clinical significance of hepatitis C virus (HCV) antiviral resistance	13
Evaluation of early antibiotic use in patients with non‐severe COVID‐19 without bacterial infection	13
Permeability enhancers sensitize β-lactamase-expressing Enterobacteriaceae and Pseudomonas aeruginosa to β-lactamase inhibitors, thereby restoring their β-lactam susceptibility	13
Synergistic phage–surfactant combination clears IgE-promoted Staphylococcus aureus aggregation in vitro and enhances the effect in vivo	13
Frequency of Long QT in Patients with SARS-CoV-2 Infection Treated with Hydroxychloroquine: A Meta-analysis	13
Genotypes, carbapenemase carriage, integron diversity and oprD alterations among carbapenem-resistant Pseudomonas aeruginosa from Russia	13
Contribution of β-lactamase and efflux pump overproduction to tazobactam-piperacillin resistance in clinical isolates of Escherichia coli	13
Antibody-based strategies in HIV therapy	13
Determination of vancomycin exposure target and individualised dosing recommendations for neonates: model-informed precision dosing	13
Short- versus standard-course intravenous antibiotics for peri-prosthetic joint infections managed with debridement and implant retention: a randomised pilot trial using a desirability of outcome rank	13
Zidovudine in synergistic combination with fosfomycin: an in vitro and in vivo evaluation against multidrug-resistant Enterobacterales	13
4-Ethoxybenzoic acid inhibits Staphylococcus aureus biofilm formation and potentiates biofilm sensitivity to vancomycin	13
Combination of polymyxin B and minocycline against multidrug-resistant Klebsiella pneumoniae: interaction quantified by pharmacokinetic/pharmacodynamic modelling from in vitro data	13
Evaluating the emergence of nonsusceptibility among Pseudomonas aeruginosa respiratory isolates from a phase-3 clinical trial for treatment of nosocomial pneumonia (ASPECT-NP)	13
Potent inhibitory activity of taniborbactam towards NDM-1 and NDM-1Q119X mutants, and in vitro activity of cefepime/taniborbactam against MBLs producing Enterobacterales	13
Assessment of cefepime toxicodynamics: comprehensive examination of pharmacokinetic/pharmacodynamic targets for cefepime-induced neurotoxicity and evaluation of current dosing guidelines	13
Within-host resistance evolution of a fatal ST11 hypervirulent carbapenem-resistant Klebsiella pneumoniae	13
Epidemiology and age-related mortality in critically ill patients with intra-abdominal infection or sepsis: an international cohort study	13
Discovery of macrozones, new antimicrobial thiosemicarbazone-based azithromycin conjugates: design, synthesis and in vitro biological evaluation	13
Preferences regarding antibiotic treatment and the role of antibiotic resistance: A discrete choice experiment	12
The effect of Ginkgolide B combined with fluconazole against drug-resistant Candida albicans based on common resistance mechanisms	12
Incidence of a subsequent carbapenem-resistant Enterobacteriaceae infection after previous colonisation or infection: a prospective cohort study	12
Population pharmacokinetics of continuous infusion of piperacillin/tazobactam in very elderly hospitalized patients and considerations for target attainment against Enterobacterales and Pseudomonas ae	12
Beta-lactam target attainment and associated outcomes in patients with bloodstream infections	12
Efficacy of cefiderocol- vs colistin-containing regimen for treatment of bacteraemic ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii in patients with COVID-19	12
Outpatient antibiotic use associated with acute upper respiratory infections in China: a nationwide cross-sectional study	12
Nirmatrelvir and COVID-19: development, pharmacokinetics, clinical efficacy, resistance, relapse, and pharmacoeconomics	12
Serum Trimethylamine-N-oxide Concentrations in People Living with HIV and the Effect of Probiotic Supplementation	12
Current Status and Structure Activity Relationship of Privileged Azoles as Antifungal Agents (2016–2020)	12
Temocillin versus carbapenems for urinary tract infection due to ESBL-producing Enterobacteriaceae: a multicenter matched case-control study	12
Impact of a non-compulsory antifungal stewardship program on overuse and misuse of antifungal agents in a tertiary care hospital	12
Effects of different resistance mechanisms on antimicrobial resistance in Acinetobacter baumannii: a strategic system for screening and activity testing of new antibiotics	12
Comparative assessment of the effects of bumped kinase inhibitors on early zebrafish embryo development and pregnancy in mice	12
In vitro comparative activity of the new beta-lactamase inhibitor taniborbactam with cefepime or meropenem against Klebsiella pneumoniae and cefepime against Pseudomonas aeruginosa metallo-beta-lactam	12
Dissemination of a ‘rare’ extended-spectrum β-lactamase gene blaSFO-1 mediated by epidemic clones of carbapenemase-producing Enterobacter hormaechei in China	12
Bacteriophages and phage-delivered CRISPR-Cas system as antibacterial therapy	12
Mechanistic Models of COVID-19: Insights into Disease Progression, Vaccines, and Therapeutics	12